Potential of Imaging and the role for AI in the management of COVID-19
Following the turbulent months of covid19 – focused drug development, IAG’s science team has published its insights on COVID-19 imaging and the role of Artificial intelligence:
“Current landscape of Imaging and the potential role for Artificial intelligence in the management of COVID-19,”
Journal: Current Problems in Diagnostic Radiology, 27 June 2020 (in press)
Authors: Faiq Shaikh, M.D., Michael Brun Andersen M.D., Ph.D., M. Rizwan Sohail M.D, Francisca Mulero M.D., Ph.D., Omer Awan, M.D., M.P.H, Diana Dupont-Roettger Ph.D., Olga Kubassova Ph.D., Jamshid Dehmsehki Ph.D., Sotirios Bisdas, M.D., Ph.D
Medical imaging plays a key role in the management of COVID-19. The computed tomography (CT) is the predominant imaging modality for diagnosing and monitoring pneumonia and pulmonary embolism caused by SARS-CoV2. There is an increasing role for MRI in the detection of the neurological complications of this disease. The article highlights the current knowledge and shares insights in the following modalities: CT, MRI, FDG-PET/CT.
We further describe the use of artificial intelligence (AI) methodologies in the management of drug development in COVID-19. Firstly, how to use AI to harness the true potential of the aforementioned imaging scans to provide prognostic insights to the disease and how to automate the process of COVID-19 detection, where the sub-specialty imaging experts are either unavailable or overwhelmed.
The paper highlights the most salient articles that demonstrate the impact AI is having in this space.
The key areas of AI has been leveraged in COVID19 management include:
- Automated detection on CT chest and plain film radiography,
- Differentiating COVID-19 from other pneumonia,
- Development of quantifiable imaging biomarkers for prognostication of COVID-19,
- Imaging-based severity assessment of COVID-19 patients.
The wealth of knowledge and the experience of radiologists and imaging researchers in COVID-19 is growing. As AI becomes a more integral part of this process, we are bound to make a greater impact in the management of not only COVID-19 but also other similar disease entities.
To explore further or to discuss your covid19 study, speak to our expert team: email@example.com
We acknoledge contribution of and thank our collaborators from the Mayo Clinic (USA), Herlev Gentofte Hospital and Aarhus University (Denmark), University College London (UK) and Centro Nacional de Investigaciones Oncológicas (Brasil).
“The wealth of knowledge and the experience of radiologists and imaging researchers in COVID-19 is growing. As AI becomes a more integral part of this process, we are bound to make a greater impact in the management of not only COVID-19 but also other similar disease entities”, commented Dr Faiq Shaikh, the Head of Research & Enterprise at IAG, and the first author on this paper. Dr. Olga Kubassova, the CEO of IAG and co-author on this paper shared her views as well, “It is important to all of us, @IAG to suppot our partners in their drug development efforts, often thinking thought fast and efficient repositioningof their existign drugs. It is inspiring to see our collaborators with different expertise and background coming together to do so.”
IAG, Image Analysis Group is a strategic partner to bio-pharmaceutical companies developing new treatments to improve patients’ lives. We fuse decades of therapeutic insights, risk-sharing business model and agile culture to accelerate novel drug development. IAG broadly leverages its core imaging expertise, proprietary technology platform DYNAMIKA and capabilities to support an objective early go no/ go decision and drive excellence for tomorrow’s innovative therapeutic agents with speed.